Mandate

Vinge advises Actic Group AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised Actic Group AB (publ) (”Actic”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on 28 March 2017 and the first day of trading on Nasdaq Stockholm was 7 April 2017.

The offer price was SEK 50.50 per share, corresponding to a market value for Actic of approximately SEK 800 million. The offer related to 8 613 860 shares, of which 5 346 534 were newly issued shares and 3 267 326 were existing shares which were offered by the selling shareholder Actic International S.à r.l., which is owned by IK 2007 Fund. The total value of the offer amounted to approximately SEK 500 million on the assumption that the oversubscription option is exercised in full.

Actic is a North European operator of health care facilities focusing on Sweden, Norway and Germany, and with a presence in Finland and Austria. As per 31 December 2016, Actic had approximately 211 000 members divided into 166 facilities in five countries with approximately 700 employees. During 2016, Actic’s total revenues amounted to approximately SEK 800 million. The company was formed in 1981 and its head office is situated in Solna.

Vinge’s team primarily consisted of Jonas Bergström, Jesper Schönbeck, David Andersson, Joel Wahlberg, Annika Nyberg Ekenberg and Christian Brelin. Linda Sengul, Johanna Wiberg and Marith Welin Berger provided advice regarding due diligence. Louise Brorsson Salomon, Helena Håkansson and Adam Sandberg provided advice relating to financing issues.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026